Skip to main
  1. Stocks
  2. United Therapeutics
  3. Forecast
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 46%
Hold 15%
Sell 0%
Strong Sell 8%

Bulls say

United Therapeutics is supported by a durable treprostinil franchise that is now diversified across inhaled, parenteral, and oral routes, giving physicians flexibility and underpinning a record $503.8M Tyvaso quarter in 3Q26, with Tyvaso DPI alone rising to $378.5M. The outlook is further strengthened by improving PH-ILD momentum after the Yutrepia settlement, which reduces competitive pressure, plus the April 26, 2027 FDA decision for Tyvaso in IPF, a large unmet market of about 100K U.S. patients that could meaningfully expand the addressable opportunity. Additional upside comes from ralinepag, which cut clinical worsening risk by 55% in Phase 3 and has a June 24, 2027 FDA target date, while the company’s broader pipeline and share buybacks support long-term growth and capital returns.

Bears say

United Therapeutics is facing a more challenging competitive and regulatory backdrop as long-term upside from its prostacyclin franchise is pressured by emerging treprostinil alternatives, including TPIP’s once-daily dosing advantage versus Tyvaso’s four-times-daily regimen. The company’s core risk is that TPIP could improve convenience and adherence if it succeeds, while its own soft-mist inhaler, Tresmi, has already seen its NDA filing pushed to 2027, signaling slower execution and delaying a potential lifecycle extension. More broadly, downside remains tied to clinical execution, regulatory uncertainty, intellectual property risk, and pricing pressure, all of which threaten a business that derives the majority of revenue in the United States and depends heavily on Tyvaso DPI.

United Therapeutics (UTHR) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 46% recommend Buy, 15% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

United Therapeutics (UTHR) Analyst Forecast & Price Prediction

Get the latest United Therapeutics (UTHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in United Therapeutics (UTHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 13 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $646.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $646.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


United Therapeutics (UTHR) Analyst Forecast & Price Prediction

Get the latest United Therapeutics (UTHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in United Therapeutics (UTHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover UTHR stock data and trends